

Supplemental Table 2. Data of Representative Adjuvant Chemotherapy

Regimen	Groups	5-year overall survival rates	5-year disease-free survival rates	Percentages of adverse reactions	Main toxicity	Treatment related death	Studies (Targeted stages)
CDDP+VDS, VB, VNR or EP	Untreated Adjuvant	40.4% 44.5%	34.3% 39.4%	Grade 4; 22.6%	Neutropenia, thrombocytopenia, and vomiting	0.8%	IALT (Stage I-III)
CBDCA+TAX	Untreated Adjuvant	58% 60%	48% 52%	Grade 4; 28%	Neutropenia	none	CALGB (Stage IB)
CDDP+VNR	Untreated Adjuvant	54% 69%	49% 61%	Grade 3 or 4; 73%	Neutropenia	0.8%	JBR10 (Stage I-II)
CDDP+VNR±radiotherapy	Untreated Adjuvant	42.6% 51.2%	not reported not reported	Grade 3 or 4; 85%	Neutropenia	2.0%	ANITA (Stage IB-IIIa)
UFT	Untreated Adjuvant	74.0% 85.0%	not reported not reported	Grade 3; 1%, Grade 4; 0%	Anorexia and nausea or vomiting	none	Stage IB adenocarcinoma
S-1	Adjuvant	72.5%	67.5%	Grade 3; 20%, Grade 4; 0%	Neutropenia and Anorexia	none	Present (Stage IB-IIIa)

CDDP = Cisplatin, VDS = Vindesine, VB = Vinblastine, VNR = Vinorelbine, CBDCA = Carboplatin, TAX = Paclitaxel.